GM2-gangliosidosis, AB variant

From WikiMD.org
Jump to navigation Jump to search

GM2-gangliosidosis, AB variant (pronunciation: /ɡiː ɛm tuː ɡæŋɡliːoʊsaɪˈdoʊsɪs, eɪ biː vɛəriənt/) is a rare genetic metabolic disorder that affects the body's ability to break down a specific type of fat called GM2 gangliosides.

Etymology

The term "GM2-gangliosidosis" is derived from the name of the fat that accumulates in the body's cells and tissues, "GM2 gangliosides". The "AB variant" refers to the specific type of this disorder.

Symptoms

The symptoms of GM2-gangliosidosis, AB variant include neurological problems, developmental delay, and vision loss.

Causes

GM2-gangliosidosis, AB variant is caused by mutations in the GM2A gene. These mutations lead to a deficiency of the GM2 activator protein, which is necessary for the normal breakdown of GM2 gangliosides.

Diagnosis

Diagnosis of GM2-gangliosidosis, AB variant is based on the clinical symptoms, genetic testing, and the measurement of the GM2 activator protein in the patient's white blood cells or skin cells.

Treatment

There is currently no cure for GM2-gangliosidosis, AB variant. Treatment is supportive and aims to manage the symptoms.

Prognosis

The prognosis for individuals with GM2-gangliosidosis, AB variant is generally poor, with most affected individuals not surviving past early childhood.

See also

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski